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Introduction
Clinical studies dating back decades report a dispro-
portionately high number of female breast cancers originating
in the upper outer quadrant of the breast [1], and although
this is attributed to a greater amount of epithelial tissue in that
region, it is also the area to which underarm cosmetic
products are applied [2,3]. Early studies reported 31% of
cancers in the upper outer quadrant [1], but later studies in
the 1990s report up to 61% [2,3]. The annually recorded
quadrant incidence of breast cancer in Britain documents a
rise in England and Wales from 47.9% in the upper outer
quadrant in 1979 to 53.3% in 2000, and in Scotland a rise
from 38.3% in the upper outer quadrant in 1980 to 54.7% in
2001 [4]. Any increase in the disproportionality of breast
cancer in the upper outer quadrant would be inconsistent
with an explanation relating to the greater amount of target
epithelial tissue in that region but does parallel the increasing
use of cosmetics in the underarm area [2-5].
How could a link exist mechanistically between
underarm cosmetics and breast cancer?
An extensive number of cosmetic products are applied
topically on and around the human breast on a daily basis,
often multiple times a day, including not only underarm anti-
perspirant/deodorant products but also body lotions, body
sprays, moisturising creams, breast firming/enhancing
creams and suncare products. These products are not rinsed
off but left on the skin, allowing for continuous dermal
exposure, absorption and deposition into underlying tissues,
which may be further increased by abrasions in the skin
created by shaving [2,3,5-7]. The extent to which chemicals
absorbed by this route escape metabolism remains unknown,
but they would certainly escape the systemic metabolism to
which orally derived chemicals would be subjected [5-7].
With current cultural pressures, these products are used with
increasing frequency and quantity [8,9], and by ever younger
children including babies [3], and the effects of long-term
low-dose exposure to these mixtures of multiple chemicals
are unknown. The diversity in usage of these cosmetics and
the range of different products available provides ample
possibility for cancer to arise through issues of quantity used,
through pattern of usage or through individual susceptibility
to specific product formulations [2,3,5-7].
Underarm cosmetics contain a variety of chemicals added for
different functional reasons (see Table 1), many of which
individually already have a known toxicity profile [5-7]. If any of
these chemicals play a role in breast cancer development,
however, then the challenge is to identify the specific chemical
culprits and their mode of action in breast epithelial cells.
Any carcinogenic action by the constituent chemicals may
involve an ability to interact with DNA, resulting in genotoxic
activity or an ability to interfere with oestrogen action [2,3,5].
The role of oestrogen in the development and progression of
breast cancer is well established [10] but the ability of a
cocktail of environmental oestrogen-mimicking chemicals to
also drive the development and growth of breast cancers is
worthy of serious consideration, especially in relation to those
chemicals known to be detectable as present in the human
breast [5]. Some studies have investigated whether environ-
mental oestrogens entering the human breast through diet
(for example, organochlorine pesticides, polychlorinated
biphenyls in animal fat, phytoestrogens or herbicides through
fruit and vegetables) or through the domestic environment
(for example, bisphenol A/phthalates in plastics, alkyl phenols
in detergents, polybrominated diphenylethers in soft furnish-
ings) may be linked to the development of breast cancer, and
topical application of cosmetic chemicals with oestrogenic
properties provides another exposure route [5].
Only two epidemiological studies have attempted to address
directly the issue of underarm cosmetic use and breast
cancer. Mirick and colleagues reported there to be no differ-
ence in current use of antiperspirant/deodorant products
between breast cancer patients and nonaffected matched
controls [11]. By contrast, McGrath reported within a
population of breast cancer patients that those who used
more antiperspirant products were diagnosed with breast
cancer at an earlier age [9]. The first study is limited by the
reliance on self-reported information, by the lack of a nonuser
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population and by the lack of consideration to historical
usage. The second study suggests a dose–response relation-
ship to chemical exposure and sensitivity at a younger age,
consistent with patterns of breast cancer development [5],
but does not exclude other risk factors or the issue that
cosmetic use is simply higher in younger women.
Oestrogenic activity of dermally absorbed
cosmetic chemicals
Many component cosmetic chemicals with oestrogenic
properties have been measured as present in human breast
tissue or human milk [5,12], and direct confirmation of the
ability of these chemicals (parabens, phthalates, sunscreens)
to be absorbed from topical application in cosmetic cream
into the human body has also been published [13-16].
Furthermore, the ability of cosmetic chemicals to be
absorbed at sufficient concentrations to exert physiological
effects is exemplified by the Mortician’s Mystery published in
the  New England Journal of Medicine in 1988 [17]. This
case report demonstrates that long-term topical exposure of
hands to embalming creams can result in endocrine disrup-
tion to the whole human body, and in particular can affect
breast tissue in males [17].
More recent studies report endocrine disruption in women at
both young and old age following inappropriate exposure to
oestrogenic chemicals in personal care products – including
premature breast development and menstruation in a 36-month
girl following exposure to hair lotion containing oestrogenic
products used by her mother [18], and, at the other extreme of
age, abnormal genital bleeding and breast cancer in a 93-year
old lady after long-term use of an ethynyloestradiol-containing
body care cream [19]. The administration of hormone
replacement therapy by skin patches relies on the ability of the
hormones to be absorbed from the patch through the skin, but
the effects of daily application over the long term of multiple
Table 1
Components of cosmetics applied to the underarm and breast area
Compounds with known 
Component Mechanism of action Examples of compounds used oestrogenic activity
Antiperspirant Mediates formation of a physical plug at  Mainly aluminium salts, often as aluminium  Aluminium is a 
the top of the sweat duct to prevent sweat  chlorhydrate metalloestrogen
escaping onto the skin surface
Deodorant To mask, modify or prevent body odour.  Phenolic compounds, often chlorinated  Triclosan
Since undesirable smell is generated  such as triclosan
through the action of bacteria on the sweat 
on the skin surface, antimicrobial agents 
act to kill bacteria
Preservative To prevent growth of microorganisms  Alkyl esters of p-hydroxybenzoic acid  Methylparaben, ethylparaben, 
during product storage (parabens) n-propylparaben, 
n-butylparaben, 
isobutylparaben, 
benzylparaben
Fragrance/  To give a good scent to the consumer  Synthetic musks, including nitromusks  Polycyclic musks HHCB, 
fragrance fixer product and polycyclic musks. Benzyl salicylate,  AHTN. Nitromusks musk 
benzyl benzoate, butylphenymethyl- xylene, musk ketone. Benzyl 
propional (Lilial) salicylate, benzyl benzoate, 
butylphenylmethylpropional
Spreading/  To ensure even distribution of  Linear (dimethicone) and cyclic  Octamethylcyclotetrasiloxane
conditioning components across the skin surface (cyclomethicone) siloxanes
Plasticiser Solvent, moisturiser, fragrance carrier Phthalates Dibutylphthalate, 
di(2-ethylhexyl)phthalate, 
diethylphthalate, 
butylbenzylphthalate
Surfactant For cleansing purposes Alkyl phenols Nonylphenol
UV filter Chemicals act to absorb UVA and UVB  Organic compounds, often  Benzophenone-3, 
light. Also added to aid product stability benzophenone derivatives benzophenone-2, 
octyl-methoxycinnamate, 
3-(4-methylbenzylidene)-
camphor, homosalate, octyl-
dimethyl-p-aminobenzoic acid
For references refer to published reviews [5-7]. HHCB, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8,-hexamethylcyclopenta-γ-2-benzopyran; AHTN, 6-acetyl-
1,1,2,4,4,7-hexamethylteralin.cosmetic products containing oestrogenic chemicals warrants
equal consideration [5].
Increasing numbers of the component chemicals in
cosmetics are now known to possess oestrogenic activity
(Table 1) [5-7]. Although many of these compounds,
including the parabens, have been termed weak oestrogens
because of their low binding affinity to the oestrogen
receptor, their efficacy is not low, and they can give the same
magnitude of response on growth of human breast cancer
cells in vitro as 17β-oestradiol when sufficient concentration
is present [5-7]. Although single chemicals considered in
isolation may or may not reach levels in the human breast that
are equivalent to those needed for measurable effects in vitro
[5-7,12], the environmental reality is that the breast is
exposed not to one but to multiple oestrogenic chemicals.
The something from nothing effect has demonstrated that
mixtures of environmental oestrogens at their no-observed-
effect concentrations can give measurable oestrogenic res-
ponses  in vitro [20], and we have found the same when
mixing five different parabens (Figure 1). Furthermore,
mixtures of the five parabens can also increase an oestro-
genic response at low levels of oestradiol (Figure 1), as might
be found at times of low oestrogen concentrations in the
menstrual cycle [21], before puberty or after menopause. The
breast is known to be susceptible to breast cancer develop-
ment prior to puberty [22] and in reality most symptoms
occur after the menopause [23].
Genotoxic properties of the chemical
components
Clinical studies in 2004 reported increased levels of genomic
instability in outer regions of the breast in histologically
normal tissue [24], which was suggested to result from
exposure to genotoxic chemicals in that region [25].
Instability of the genome is an important contributor to
genetic changes that drive carcinogenic processes, and in
accordance with the cancer field theory could provide a
milieu where genetically altered cells would be more
susceptible to the development of cancer [5,24,25].
The active antiperspirant agents are aluminium salts – and
aluminium has a known genotoxic profile [26,27], and
aluminium chlorhydrate has been shown active in the Comet
assay [28]. Use of these salts in cosmetics relies on the
inability of the antiperspirant complexes to be absorbed [8].
Dermal absorption of aluminium from topically applied
antiperspirant aluminium chlorhydrate, however, has been
demonstrated through intact human skin of the underarm
[29], and aluminium was measured in human breast tissue at
greater levels in outer quadrants than in inner quadrants [30].
Clinical consequences arising from absorbed antiperspirant
salts were described in a case study in 2004 reporting
adverse bone pain and fatigue associated with toxic blood
levels of aluminium, both of which disappeared after
discontinuing antiperspirant use [31].
Could there be a link to inherited
susceptibility to breast cancer?
Development of breast cancer through the inheritance of
genetic susceptibility is associated with loss of function of
tumour suppressor genes including the BRCA1 and BRCA2
genes, which results in impaired DNA repair processes [32].
The increasing penetrance of these genes in Iceland,
however, has suggested that underlying mechanisms of
susceptibility can also be influenced by environmental factors
as well as genetic factors [33]. Although it is possible that
cancers result in these susceptible people from an inability to
repair random replication errors, it is also possible that these
people are more susceptible to damage from genotoxic
pollutant chemicals, including those absorbed from cosmetic
products applied around the breast area, than the remainder
of the population who have intact DNA repair systems [2,3,5].
Antiperspirant use and breast cysts
Although cancer assumes the highest profile, it represents
only about 5% of clinical abnormalities of the human breast,
with breast cysts and fibroadenomas being the most common
benign breast abnormalities [1]. The reason for such a high
incidence of benign breast conditions is unknown, but it is
notable that the most common site of occurrence of these
benign conditions is also the upper outer quadrant of the
breast [1-3,5].
On the basis that antiperspirant formulations are designed to
block underarm sweat ducts [8] and breast cysts arise from
blocked breast ducts in the adjacent region of the body [1], it
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Figure 1
Effect of parabens and oestradiol on growth of MCF7 human breast
cancer cells. Effect of five parabens on growth of MCF7 human breast
cancer cells individually at no-observed-effect concentration (NOEC)
values, of all five parabens mixed together at NOEC values, of 10–11 M
oestradiol (E2), or of 10–11M E2 together with all five parabens at their
NOEC values. Cells were grown and cell growth is presented as
published previously [35-37] (AK Charles, PD Darbre, University of
Reading, unpublished data).is plausible that breast cysts might also arise from
antiperspirant use if sufficient chemicals are absorbed over
long periods of usage [3,5]. The recent study reporting raised
aluminium levels in human breast cyst fluids, most notably
from type 1 cysts, compared with serum or milk [34] provides
evidence warranting further research into a link between
aluminium-based antiperspirant use and breast cyst
development.
Conclusions
Although cosmetic products were used even as long ago as
3500 BC in Ancient Egypt, the mass marketing of recent
decades has resulted in unprecedented quantities being now
used on the human body and in unprecedented exposure of
people across the whole global population. The proposed link
between breast cancer and the application of cosmetic
chemicals with oestrogenic and/or genotoxic properties
provides an evidence-based hypothesis capable of further
testing. Although individual chemicals will have been tested
by current safety guidelines, the effects of long-term usage of
mixtures of these chemicals over an entire lifetime by people
of all ages across the whole world warrants retrospective
investigation. If use of underarm cosmetics is a factor in the
development of breast cancer, then options for prevention
could at last become a reality through individual decisions to
cease usage or through alterations to product formulations.
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